# Monthly And Twice Monthly Subcutaneous Dosing Of PF-04950615 (RN316) In Hypercholesterolemic Subjects On A Statin

Study · id `cardio:ct-nct01592240` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01592240](<https://clinicaltrials.gov/study/NCT01592240>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT01592240

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 354 participants.

## Technical summary

Registry record NCT01592240. Randomized; triple masking; primary purpose treatment. Start 2012-07 (actual); primary completion 2013-04 (actual). Results posted on 2017-12-05.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 354 participants (enrolled count; ClinicalTrials.gov record NCT01592240, source copy `cardio:ctgov-nct01592240-2017-12-05`, retrieved 2026-10-31)
- Started: 2012-07 (actual) (ClinicalTrials.gov record NCT01592240, source copy `cardio:ctgov-nct01592240-2017-12-05`, retrieved 2026-10-31)
- Primary completion: 2013-04 (actual) (ClinicalTrials.gov record NCT01592240, source copy `cardio:ctgov-nct01592240-2017-12-05`, retrieved 2026-10-31)
- Completion: 2013-05 (actual) (ClinicalTrials.gov record NCT01592240, source copy `cardio:ctgov-nct01592240-2017-12-05`, retrieved 2026-10-31)
- Results first posted: 2017-12-05 (ClinicalTrials.gov record NCT01592240, source copy `cardio:ctgov-nct01592240-2017-12-05`, retrieved 2026-10-31)
- Countries: United States (ClinicalTrials.gov record NCT01592240, source copy `cardio:ctgov-nct01592240-2017-12-05`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01592240-2017-12-05`, retrieved 2026-10-31)

## The registry's words

- Brief title: Monthly And Twice Monthly Subcutaneous Dosing Of PF-04950615 (RN316) In Hypercholesterolemic Subjects On A Statin
- Condition: Hypercholesterolemia
- Intervention (Drug): PBO
- Intervention (Drug): 200mg PF-04950615 (RN316)
- Intervention (Drug): 300mg PF-04950615 (RN316)
- Intervention (Drug): PBO
- Intervention (Drug): PF-04950615
- Intervention (Drug): PF-04950615
- Intervention (Drug): PF-04950615
- Lead sponsor: Pfizer
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry lists this organization as the lead sponsor: Pfizer (`cardio:org-pfizer`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia (`cardio:pubmed-25784512`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: a5a8e137a60897f8d7b3d15825aae804ffd30fdb1f47f1366abfad9b847bf3f0
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
